Clinical Trial Search

Primary: Number of Subjects With Treatment-emergent Adverse Events — 4; 7; 10; 6 Participants

Primary: Number of Participants With Treatment-related Adverse Events ≥ Grade 2 — 1; 4 Participants

Primary: Maximum Concentration of Percent of Injected Dose in the Whole Brain (Cmax, %ID Brain) of [11C]Osimertinib — 1.465; 1.617; 1.492 percent of radioactive drug

Primary: Part A: Area Under the Concentration-time Curve (AUC) From Zero (Pre-dose) to Time of Last Quantifiable Concentration (AUC[0-t]) Following Administration of Daprodustat…

Primary: Number of Participants Experiencing Dose Limiting Toxicities — 0; 1; 7 Participants

Primary: Number of Subjects With Drug-related Adverse Events — 2; 1; 2; 1 Participants

Primary: Maximum Observed Concentration (Cmax) of BGF MDI — 552.2; 483.2; 489.4; 11.74 pg/mL

Primary: Program Engagement — 7.3; 19.9 User sessions — p=<0.01

Primary: Number of Subjects Who Experience Serious Adverse Events, Adverse Events, and/or Early Treatment Discontinuations. — 1 Participants

Primary: Percentage of Dose-limiting Toxicities — 0; 0; 17 Percentage of dose-limiting toxicities

Primary: Tolerability as Measured by Number of Participants With Related Adverse Events — 15; 1; 1; 1 Participants

Primary: Percentage of Absolute Oral Bioavailability for Quizartinib As Assessed By Pharmacokinetic Parameters for Area Under the Plasma Concentration-Time Curve Following…

Primary: Number of Participants With Unsolicited Adverse Events — 0; 0; 0; 0 Participants

Primary: Incidence of Adverse Events — 6; 7; 7; 6 Participants

Primary: Reinforcing Effects of Methamphetamine Following Methylphenidate (0 mg; Placebo) Maintenance. — 0; 0; 3.33; 7.25 Trials Completed